Cargene is a preclinical-stage biopharmaceutical company established in 2020 with a focus on developing innovative oligonucleotide therapeutics targeting liver fibrosis and ophthalmic disorders. The company, with operations in Singapore, the USA, and China, aims to enhance the quality of life for millions of patients globally. Through their unique platforms fueled by groundbreaking biology and chemistry insights, Cargene seeks to create highly specific, stable, and potent nucleic acid-based medicines to address a diverse range of diseases.
The company's slogan "Pioneering a new wave of treatments with advanced nucleic acid-based medicines to enhance lives globally" encapsulates their mission and vision. In a significant development, Cargene secured a $19.20M Seed Round investment on 14 December 2021 from Legend Star, BioTrack Capital, and Hyfinity Investments, showcasing investor confidence in the company's potential and the promising nature of their pioneering treatments.
Operating in the Biopharma, Biotechnology, and Health and Wellness industries, Cargene is at the forefront of driving advancements in nucleic acid-based medicines, positioning itself as a key player in the global quest for improved treatments and enhanced health outcomes.
